Jack A Syage1, Peter H R Green2, Chaitan Khosla3, Daniel C Adelman4, Jennifer A Sealey-Voyksner1, Joseph A Murray5. 1. ImmunogenX, Newport Beach, CA, United States. 2. Celiac Disease Center, Columbia University, New York, NY, United States. 3. Stanford University, Stanford, CA, United States. 4. Aimmune Therapeutics, Brisbane, CA, United States. 5. Mayo Clinic, Rochester, MN, United States.
Abstract
BACKGROUND: Celiac disease (CD) is a widespread autoimmune disease triggered by dietary gluten that can lead to severe gastrointestinal symptoms. Because there is no available treatment other than a lifelong gluten-free diet, many patients continue to experience chronic symptoms. AIM: In this analysis we report on the efficacy of latiglutenase, an orally administered enzyme treatment, for improving multiple gluten-induced symptoms and consequent quality of life (QOL) due to inadvertent gluten consumption. METHODS: This analysis is based on data from the CeliAction study of symptomatic patients (ALV003-1221; NCT01917630). Patients were treated with latiglutenase or placebo for 12 weeks and instructed to respond to a symptom diary daily and to multiple QOL questionnaires at weeks 0, 6, and 12 of the treatment periods as secondary endpoints. The results were stratified by serostatus. RESULTS: 398 patients completed the 12-week CDSD study. In seropositive, but not seronegative, CD patients a statistically significant and dose-dependent improvement was seen in the severity and frequency of abdominal pain, bloating, tiredness, and constipation. In subjects receiving 900 mg latiglutenase, improvements (p-values) in the severity of these symptoms for week 12 were 58% (0.038), 44% (0.023), 21% (0.164), and 104% (0.049) respectively, relative to placebo-dosed subjects. The reduction in symptoms trended higher for more symptomatic patients. Similar results were observed for the QOL outcome measures. CONCLUSIONS: Although this study was not powered to definitively establish the benefit of latiglutenase in seropositive CD patients, such patients appear to show symptomatic and QOL benefit from using latiglutenase with meals.
BACKGROUND: Celiac disease (CD) is a widespread autoimmune disease triggered by dietary gluten that can lead to severe gastrointestinal symptoms. Because there is no available treatment other than a lifelong gluten-free diet, many patients continue to experience chronic symptoms. AIM: In this analysis we report on the efficacy of latiglutenase, an orally administered enzyme treatment, for improving multiple gluten-induced symptoms and consequent quality of life (QOL) due to inadvertent gluten consumption. METHODS: This analysis is based on data from the CeliAction study of symptomatic patients (ALV003-1221; NCT01917630). Patients were treated with latiglutenase or placebo for 12 weeks and instructed to respond to a symptom diary daily and to multiple QOL questionnaires at weeks 0, 6, and 12 of the treatment periods as secondary endpoints. The results were stratified by serostatus. RESULTS: 398 patients completed the 12-week CDSD study. In seropositive, but not seronegative, CD patients a statistically significant and dose-dependent improvement was seen in the severity and frequency of abdominal pain, bloating, tiredness, and constipation. In subjects receiving 900 mg latiglutenase, improvements (p-values) in the severity of these symptoms for week 12 were 58% (0.038), 44% (0.023), 21% (0.164), and 104% (0.049) respectively, relative to placebo-dosed subjects. The reduction in symptoms trended higher for more symptomatic patients. Similar results were observed for the QOL outcome measures. CONCLUSIONS: Although this study was not powered to definitively establish the benefit of latiglutenase in seropositive CD patients, such patients appear to show symptomatic and QOL benefit from using latiglutenase with meals.
Authors: Daniel A Leffler; Sarah Acaster; Katy Gallop; Melinda Dennis; Ciarán P Kelly; Daniel C Adelman Journal: Value Health Date: 2017-02-14 Impact factor: 5.725
Authors: S Lohi; K Mustalahti; K Kaukinen; K Laurila; P Collin; H Rissanen; O Lohi; E Bravi; M Gasparin; A Reunanen; M Mäki Journal: Aliment Pharmacol Ther Date: 2007-11-01 Impact factor: 8.171
Authors: Benjamin A Lerner; Lynn T Phan Vo; Shireen Yates; Andrew G Rundle; Peter H R Green; Benjamin Lebwohl Journal: Am J Gastroenterol Date: 2019-05 Impact factor: 10.864
Authors: Daniel A Leffler; Ciaran P Kelly; Peter H R Green; Richard N Fedorak; Anthony DiMarino; Wendy Perrow; Henrik Rasmussen; Chao Wang; Premysl Bercik; Natalie M Bachir; Joseph A Murray Journal: Gastroenterology Date: 2015-02-13 Impact factor: 22.682
Authors: Jack A Syage; Ciarán P Kelly; Matthew A Dickason; Angel Cebolla Ramirez; Francisco Leon; Remedios Dominguez; Jennifer A Sealey-Voyksner Journal: Am J Clin Nutr Date: 2018-02-01 Impact factor: 7.045
Authors: Lu Shan; Øyvind Molberg; Isabelle Parrot; Felix Hausch; Ferda Filiz; Gary M Gray; Ludvig M Sollid; Chaitan Khosla Journal: Science Date: 2002-09-27 Impact factor: 47.728
Authors: Jonathan Gass; Michael T Bethune; Matthew Siegel; Andrew Spencer; Chaitan Khosla Journal: Gastroenterology Date: 2007-05-21 Impact factor: 22.682
Authors: Govind K Makharia; Prashant Singh; Carlo Catassi; David S Sanders; Daniel Leffler; Raja Affendi Raja Ali; Julio C Bai Journal: Nat Rev Gastroenterol Hepatol Date: 2022-01-03 Impact factor: 46.802
Authors: Laura Marinela Ailioaie; Constantin Ailioaie; Gerhard Litscher; Dragos Andrei Chiran Journal: Int J Mol Sci Date: 2022-07-13 Impact factor: 6.208
Authors: Sandip K Wagh; Karen M Lammers; Manohar V Padul; Alfonso Rodriguez-Herrera; Veronica I Dodero Journal: Int J Mol Sci Date: 2022-10-04 Impact factor: 6.208